(Press-News.org) Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
The ACR estimates that 161,000 to 322,000 adults in the U.S. have SLE, an autoimmune disease that can affect multiple systems in the body. Those with SLE may experience periods of increased disease activity (flares). Manifestations of lupus range from mild, single-organ involvement to more severe involving multiple organs, which can also lead to organ failure. Treatments for SLE include the off-label clinical use of immunosuppressives such as azathioprine, methotrexate, and cyclophosphamide, which may still require the use of high-dose corticosteroids. Corticosteroids, such as prednisone, are effective in treating flares, but are associated with toxicities and long-term use place patients at risk for severe comorbidities.
Prior studies have shown that abatacept is safe and effective in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). The Food and Drug Administration (FDA) and European Medicines Agency (EMA) currently approve abatacept for the treatment of moderate to severe RA and JIA, leading researchers to believe it may be an appropriate therapy for other autoimmune diseases such as SLE. "Corticosteroids have serious side effects, so treatments that are targeted and could control disease activity while allowing steroid tapering would represent an advance in lupus therapy," said lead author of the current study, Joan T. Merrill, M.D. of the Oklahoma Medical Research Foundation.
Dr. Merrill and colleagues conducted the first trial to assess the effects of abatacept on disease flares in patients with non-life threatening SLE. There were 175 patients included in the trial whose primary symptoms included active polyarthritis, chronic discoid skin lesions, pleuritis, and/or pericarditis. Participants were randomized with 118 administered abatacept (10mg/kg of body weight) by intravenous (IV) infusion on days 1, 15, 29 and every 4 weeks throughout the 12-month period. There were 57 patients in the placebo group who received normal saline IV infusion. Prednisone (30 mg/day) was administered to both groups for 1 month and then tapered.
At the completion of the study 68.6% of participants remained in the abatacept group and 61.4% in the placebo group. Researchers found the most frequent reason for discontinuation was lack of efficacy—17.8% in the abatacept group and 21.1% in the placebo cohort. Further more, the proportion of patients with a new flare following the steroid taper was 79.7% and 82.5% in the abatacept and placebo groups, respectively. In ad hoc analyses, there were greater differences when severe flares or physician-reported flares were analyzed separately, and in the subset of patients who entered the study with active arthritis, but these findings are considered exploratory and would require confirmation in future studies.
The research team also found that the frequency of patients with serious adverse events (SAEs) was higher in participants receiving abatacept (19.8%) than with those in the placebo group (6.8%). SAEs were single events ranging from nausea to lupus nephritis, and most often occurred during the first 6 months of the study, including the 2-month steroid taper period. Researchers suggest that the majority of SAEs could be attributed to SLE disease activity.
"While there is potential for clinical application of abatacept, further studies are needed to evaluate whether there are subsets of patients for whom this treatment might be useful, and then to determine the best way to treat and monitor such patients," concluded Dr. Merrill.
INFORMATION:
Article: "The Efficacy and Safety of Abatacept in Patients with Non–Life Threatening Manifestations of Systemic Lupus Erythematosus." J. T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D. J. Wallace, S. C. Bae, L. Sigal, J.-C. Becker, S. Kelly, K. Raghupathi, T. Li, Y. Peng, M. Kinaszczuk, and P. Nash. Arthritis & Rheumatism; Published Online: June 8, 2010 (DOI: 10.1002/art.27601); Print Issue Date: October 2010. http://onlinelibrary.wiley.com/doi/10.1002/art.27601/abstract
This study is published in Arthritis & Rheumatism. Media wishing to receive a PDF of the articles may contact healthnews@wiley.com.
Arthritis & Rheumatism is an official journal of the American College of Rheumatology and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. For details please visit, http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
About Wiley-Blackwell
Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.
NASA is providing data from three satellites to give forecasters valuable information on newly strengthened Tropical Storm Nicole. Nicole was Tropical Depression 16 until 11 a.m. EDT, Sept. 29 and NASA data helped confirm her new designation. Satellite data from NASA showed frigid thunderstorm cloud top temperatures, heavy rainfall, and extensive cloud cover as Nicole strengthened.
The Atmospheric Infrared Sounder (AIRS) instrument uses infrared technology to take a tropical cyclone's temperature. AIRS sits on NASA's Aqua satellite and captured an image of those cloud ...
PHILADELPHIA –- Computational biologists at the University of Pennsylvania say that species are still accumulating on Earth but at a slower rate than in the past.
In the study, published in the journal PLoS Biology, Penn researchers developed a novel computational approach to infer the dynamics of species diversification using the family trees of present-day species. Using nine patterns of diversification as alternative models, they examined 289 phylogenies, or evolutionary trees, representing amphibians, arthropods, birds, mammals, mollusks and flowering plants.
The ...
The Department of the Interior, the National Oceanic and Atmospheric Administration, and the co-trustees for natural resources affected by the BP/Deepwater Horizon oil spill announced today they have started the injury assessment and restoration planning phase of the Natural Resource Damage Assessment, a legal process to determine the type and amount of restoration needed to compensate the public for harm to natural resources and their human uses as a result of the spill.
This is the second phase of the NRDA process. Much of the initial "preassessment" phase has already ...
A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.
"The consistency in the trends from cigarette sales and population surveys was reassuring" said John P. Pierce, PhD, Sam M. Walton Professor of Cancer Research in the Department of Family and Preventive Medicine at UCSD School of Medicine and director of the Population Sciences Division at Moores UCSD Cancer Center. "What is really important is that the widening ...
September 28, 2010 – Although first responders willingly put themselves in harm's way during disasters, new research indicates that they may not be as willing— if the disaster is a potentially lethal pandemic.
In a recent study, researchers at Columbia University's Mailman School of Public Health found that more than 50% of the first responders and other essential workers they surveyed might be absent from work during a serious pandemic, even if they were healthy.
The study, reported online in the October issue of the Journal of Occupational and Environmental Medicine, ...
ANN ARBOR, Mich.---Apparently your mom had it right when she threatened to wash your mouth out with soap if you talked dirty. Lying really does create a desire to clean the "dirty" body part, according to a University of Michigan study.
"The references to 'dirty hands' or 'dirty mouths' in everyday language suggest that people think about abstract issues of moral purity in terms of more concrete experiences with physical purity," said Spike W.S. Lee, a U-M doctoral candidate in psychology, who conducted the study with Norbert Schwarz, a psychologist at the U-M Institute ...
Social promotions such as those offered by deal-of-the-day website Groupon are wildly popular with shoppers, but they might not be as big a hit for businesses, according to a recent study by Rice University's Jesse H. Jones Graduate School of Business.
Groupon promotions were profitable for 66 percent of the businesses surveyed for the study, but they were unprofitable for 32 percent. More than 40 percent of the respondents indicated they would not run such a promotion again.
Groupon is a social promotion site that features a daily deal for each city in which it operates ...
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
"This is the ...
A research and development effort by the University of Notre Dame, the University of Wyoming, and Kraig Biocraft Laboratories, Inc. has succeeded in producing transgenic silkworms capable of spinning artificial spider silks.
"This research represents a significant breakthrough in the development of superior silk fibers for both medical and non-medical applications," said Malcolm J. Fraser Jr., a Notre Dame professor of biological sciences. "The generation of silk fibers having the properties of spider silks has been one of the important goals in materials science."
Natural ...
A CEO's fate might be in the hands of external constituents, according to a new study from Rice University's Jones Graduate School of Business. The study found that investment analysts and their negative stock ratings can sway a board to dismiss its CEO.
Conventional research has focused on internal factors that contribute to CEO dismissal -- poor firm performance and organization power and politics. But the new study, published by the Strategic Management Journal, turned its attention outward to discover the significant influence investment analysts have on a board ...
